Notice of AGM and Posting of Annual Report

Summary by AI BETAClose X

Vulcan Two Group plc has announced that its Annual General Meeting will be held on Wednesday, 24 June 2026, and has made its Annual Report and Accounts for the year ended 31 December 2025 available to shareholders online and by mail to those who have elected for hard copies. The company, focused on building the UK's leading regulated ePharmacy, recently completed acquisitions of CloudRx, Webmed, and Hyperdrug in March 2026, establishing a profitable platform with recurring revenues and strong cash generation.

Disclaimer*

Vulcan Two Group PLC
27 May 2026
 

27 May 2026

 Vulcan Two Group plc

(the "Company" or "Vulcan Two")

 

Notice of Annual General Meeting and Posting of Annual Report

 

Vulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy and build, announces that the Company's Annual General Meeting ("AGM") will be held at 2:00pm on Wednesday, 24 June 2026 at Canaccord Genuity Limited, 88 Wood Street, London, EC2V 7QR.

 

The Annual Report and Accounts for the year ended 31 December 2025, together with the Notice of Annual General Meeting, have been made available to shareholders on the company's website at www.vulcantwo.com/investors   

 

The Notice of the AGM, Annual Report, and Form of Proxy have been mailed to shareholders who have elected to receive hard copies.

 

 

For further information please contact:

 

Vulcan Two Group plc

Michael Kraftman, Chief Executive Officer

Keith Butcher, Chief Financial Officer

Brendan O'Brien, Chief Operating Officer

Email: info@vulcantwo.com

 

Canaccord Genuity Limited
(Nominated Adviser and Sole Broker)

Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott

Tel: +44 (0) 20 7523 8000

Alma Strategic Communications
(Financial PR)

Justine James / Sam Modlin / Will Merison

Email: vulcantwo@almastrategic.com

Tel: +44 (0) 20 3405 0205

 

Notes to Editors

Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise.

For more information, visit www.vulcantwo.com   

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings